|
|
SciBX: Science-Business eXchange
Collection on Brown Fat
This special collection from SciBX: Science-Business eXchange provides an overview of the state of affairs on brown fat from the scientific, business and regulatory perspectives.
Click here to access the Collection for free!
Sponsored by:
Ember Therapeutics
AstraZeneca | | | |
 |
| |
Analysis |
 |
Cover Story |  Top |
|
 |
|
|
Putting on the brakes
Tracey Baas
doi:10.1038/scibx.2014.40
A group at Memorial Sloan-Kettering Cancer Center has developed T cells that express an inhibitory chimeric antigen receptor, or iCAR, in addition to a cancer-specific CAR to prevent healthy cells from activating T cell function. The team will next use the strategy to produce iCAR T cells to target cancer cells in solid tumors.
Full Text | PDF |
|
|
|
|
|
|
Translational Notes | Top |
|
|
|
|
Biotech kibbutz
Lev Osherovich
doi:10.1038/scibx.2014.41
Johnson & Johnson and Takeda have partnered with the Israeli government and OrbiMed Israel Partners to build FutuRx, a collectively owned biotech incubator. The incubator is part of a global portfolio of partnerships and investments by Johnson & Johnson Innovation, the pharma's early stage collaborations unit.
Full Text | PDF |
|
|
|
|
|
|
Targets and Mechanisms | Top |
|
|
|
|
Putting a lid on cancer cell proteasomes
Benjamin Boettner
doi:10.1038/scibx.2014.42
A Johns Hopkins University team has discovered a compound, RA190, which suppresses tumor growth by blocking the regulatory subunit of proteasomes. The team is now working on enhancing the compound's drug-like properties and is testing it in clinical isolates from patients with multiple myeloma.
Full Text | PDF |
|
|
|
|
|
|
Melanoma checkpoint inhibitors
Lauren Martz
doi:10.1038/scibx.2014.43
U.S. researchers have found that a cocktail of antibodies targeting checkpoint proteins and peptide-based cancer vaccines induced a potent and tumor-specific T cell response to treat melanoma.
Full Text | PDF |
|
|
|
|
|
|
Distillery: Therapeutics |
|
Autoimmune disease | Top |
|
|
|
|
S100 calcium binding protein A9 (S100A9; calgranulin B; MRP14); complement 3 (C3)
doi:10.1038/scibx.2014.44
Studies in human samples and mice suggest inhibiting S100A9 or C3 could help treat psoriasis.
Full Text | PDF |
|
|
|
|
Cancer | Top |
|
|
|
|
l-Asparagine
doi:10.1038/scibx.2014.45
Cell culture and mouse studies identified mutants of Escherichia coli l-asparaginase II (EcA) that could help treat ALL.
Full Text | PDF |
|
|
|
|
 |
|
Cytochrome P450 family 27 subfamily A polypeptide 1 (CYP27A1)
doi:10.1038/scibx.2014.46
Mouse studies suggest lowering cholesterol or inhibiting CYP27A1 could help treat estrogen-dependent breast cancer.
Full Text | PDF |
|
|
|
|
|
|
S100 calcium binding protein A14 (S100A14); HER2 (EGFR2; ErbB2; neu)
doi:10.1038/scibx.2014.47
In vitro studies suggest inhibiting S100A14 could help treat HER2+ breast cancer.
Full Text | PDF |
|
|
|
|
|
|
Adhesion regulating molecule 1 (ADRM1; RPN13)
doi:10.1038/scibx.2014.48
In vitro and mouse studies suggest inhibiting the RPN13 proteasomal component could help treat cancer.
Full Text | PDF |
|
|
|
|
|
|
Endoplasmic reticulum aminopeptidase 1 (ERAP1; ARTS1; ERAAP); ERAP2; insulin-regulated aminopeptidase (IRAP)
doi:10.1038/scibx.2014.49
In vitro and mouse studies identified inhibitors of ERAP1, ERAP2 and IRAP that could help treat inflammation or cancer.
Full Text | PDF |
|
|
|
|
|
|
TTK protein kinase (TTK; MPS1)
doi:10.1038/scibx.2014.50
In vitro and cell culture studies identified an orally bioavailable small molecule inhibitor of MPS1 that could help treat cancer.
Full Text | PDF |
|
|
|
|
|
|
Fc fragment of IgG receptor transporter-α (FCGRT; FCRN)
doi:10.1038/scibx.2014.51
Mouse studies suggest activating FCGRT on dendritic cells could help stimulate an immune response against colorectal cancers.
Full Text | PDF |
|
|
|
|
|
|
Bromodomain containing 4 (BRD4); BRD2; BRD3
doi:10.1038/scibx.2014.52
Cell culture and mouse studies suggest BET inhibitors of BRD2, BRD3 and BRD4 could help treat diffuse large B cell lymphoma (DLBCL).
Full Text | PDF |
|
|
|
|
|
|
IKAROS family zinc finger 1 (IKZF1; LYF1); IKZF3; cereblon (CRBN)
doi:10.1038/scibx.2014.53
In vitro studies identified degradation of IKZF1 and IKZF3 as the anticancer mechanism of Revlimid lenalidomide.
Full Text | PDF |
|
|
|
|
|
|
ATG5 autophagy related 5 homolog (ATG5); ATG7; K-Ras (KRAS); p53
doi:10.1038/scibx.2014.54
Mouse studies suggest inhibiting autophagy in KRAS-driven pancreatic ductal adenocarcinomas (PDACs) lacking p53 could accelerate tumor formation.
Full Text | PDF |
|
|
|
|
Endocrine/metabolic disease | Top |
|
|
|
|
Pancreatic and duodenal homeobox 1 (PDX1; IPF1)
doi:10.1038/scibx.2014.55
In vitro studies identified a small molecule that increases PDX1 expression and could help treat diabetes.
Full Text | PDF |
|
|
|
|
Infectious disease | Top |
|
|
|
|
Not applicable
doi:10.1038/scibx.2014.56
In vitro and rodent studies identified cytoplasmic rRNA–targeted aminoglycoside derivatives that could help treat bacterial infections and certain genetic diseases with fewer side effects than approved aminoglycosides.
Full Text | PDF |
|
|
|
|
|
|
HCV E2
doi:10.1038/scibx.2014.57
In vitro studies solved the structure of the HCV E2 protein, which could aid HCV vaccine and drug design.
Full Text | PDF |
|
|
|
|
|
|
Mucin 5B oligomeric mucus/gel-forming (MUC5B)
doi:10.1038/scibx.2014.58
Mouse studies suggest maintaining baseline MUC5B expression is necessary to promote the clearance of pathogens from respiratory surfaces.
Full Text | PDF |
|
|
|
|
|
|
Tissue factor pathway inhibitor 2 (TFPI-2; PP5)
doi:10.1038/scibx.2014.59
Studies in human plasma and mice suggest the TFPI-2 peptide EDC34 could help treat sepsis.
Full Text | PDF |
|
|
|
|
|
|
Mycobacterium tuberculosis cell division protein FtsZ (MtbftsZ)
doi:10.1038/scibx.2014.60
In vitro studies identified a new class of MtbftsZ inhibitors that could help treat tuberculosis.
Full Text | PDF |
|
|
|
|
|
|
Tryptophan synthesis
doi:10.1038/scibx.2014.61
In vitro and mouse studies suggest inhibiting bacterial tryptophan synthesis could help treat tuberculosis.
Full Text | PDF |
|
|
|
|
Neurology | Top |
|
|
|
|
Chromosome 9 open reading frame 72 (C9orf72)
doi:10.1038/scibx.2014.62
A study of patient samples suggests reducing levels of transcripts made from C9orf72 repeat expansions could help treat ALS.
Full Text | PDF |
|
|
|
|
|
|
Myocyte enhanced factor 2C (MEF2C)
doi:10.1038/scibx.2014.63
In vitro studies suggest increasing MEF2C expression could help treat PD.
Full Text | PDF |
|
|
|
|
Various | Top |
|
|
|
|
Caspase recruitment domain family member 15 (CARD15; NOD2)
doi:10.1038/scibx.2014.64
Mouse studies suggest stimulating NOD2 could help treat atherosclerosis and periodontal bone loss.
Full Text | PDF |
|
|
|
|
Distillery: Techniques |
|
Assays and screens | Top |
|
|
|
|
A point-of-care device for obtaining T cell counts from whole blood of HIV-infected individuals
doi:10.1038/scibx.2014.65
A battery-powered, handheld device for on-chip sample preparation and counting of CD4+ and CD8+
Full Text | PDF
|
|
|
|
|
|
|
Coupled ligand affinity capture and massively parallel DNA sequencing (Chem-seq) for genome-wide mapping of interactions between small molecules and chromatin
doi:10.1038/scibx.2014.66
Chem-seq can help map interactions between small molecules and their protein targets in chromatin of cells.
Full Text | PDF |
|
|
|
|
Chemistry | Top |
|
|
|
|
Synthetic, homogenous erythropoietin (EPO)
doi:10.1038/scibx.2014.67
Solid-phase synthesis of homogenous, glycosylated EPO could lead to synthetic approaches for manufacture of biologics.
Full Text | PDF |
|
|
|
|
Drug platforms | Top |
|
|
|
|
A multifunctional, aptamer-based DNA nanoassembly (AptNA) for targeted cancer therapy
doi:10.1038/scibx.2014.68
In vitro and cell culture studies suggest AptNAs that deliver small molecule and antisense compounds could help treat cancer.
Full Text | PDF |
|
|
|
|
|
|
Antigen-specific inhibitory chimeric antigen receptors (iCARs) as a self-regulating safety switch to constrain T cell–based therapies
doi:10.1038/scibx.2014.69
Antigen-specific iCARs could be used as a self-regulating safety switch to constrain T cell–based therapies and avoid off-tumor toxicity.
Full Text | PDF |
|
|
|
|
|
|
Generation of metanephric nephron progenitor cells from pluripotent stem cells for 3D kidney modeling in vitro
doi:10.1038/scibx.2014.70
Induced metanephric nephron progenitor cells could help model kidney diseases.
Full Text | PDF |
|
|
|
|
|
|
Human pluripotent stem cell–derived lung and airway epithelial cells
doi:10.1038/scibx.2014.71
Human pluripotent stem cell–derived lung and airway epithelial cells could be used to model respiratory diseases.
Full Text | PDF |
|
|
|
|
|
|
Knockout chickens created by homologous recombination in primordial germ cells (PGCs)
doi:10.1038/scibx.2014.72
Homologous recombination in PGCs could be used to make genetic knockout chickens and aid the production of engineered antibodies.
Full Text | PDF |
|
|
|
|
Instrumentation | Top |
|
|
|
|
Microfluidic electrochemical detector for in vivo continuous monitoring (MEDIC) of therapeutics
doi:10.1038/scibx.2014.73
MEDIC may allow real-time, continuous monitoring of therapeutics in patients.
Full Text | PDF |
|
|
|
|
Markers | Top |
|
|
|
|
Phosphatidylinositol-3,4,5-triphosphate–dependent Rac exchange factor 1 (PREX1) levels predict response to phosphoinositide 3-kinase (PI3K) inhibition
doi:10.1038/scibx.2014.74
In vitro studies suggest PREX1 expression in breast cancer could help predict sensitivity to PI3K inhibitors.
Full Text | PDF |
|
|
|
|
| Top |
|
 |
No comments:
Post a Comment